Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161644 | 1.00 | TSHR (0.51) | TSHRSMN1; SMN2PTGS2PTGS1KMT2A | |
| SCHEMBL18593 | 0.83 | BRD1 (0.42) | PTGS2PTGS1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL4355804 | 0.83 | TSHR (0.54) | TSHRSMN1; SMN2PTGS2PTGS1KMT2A | |
| SCHEMBL2329775 | 0.81 | PTGS2 (0.64) | TSHRSMN1; SMN2PTGS2PTGS1KMT2A | |
| SCHEMBL68413 | 0.80 | KMT2A (0.48) | PTGS2PTGS1KMT2AMEN1ALDH1A1 | |
| SCHEMBL994541 | 0.80 | TDP1 (0.61) | TSHRPTGS2KMT2AHTTMEN1 | |
| SCHEMBL30775361 | 0.79 | PTGS2 (0.65) | TSHRSMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL3900014 | 0.79 | PTGS2 (0.65) | TSHRSMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL13751192 | 0.79 | TSHR (0.54) | TSHRSMN1; SMN2PTGS2PTGS1KMT2A | |
| SCHEMBL14837371 | 0.78 | TSHR (0.50) | TSHRSMN1; SMN2PTGS2PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025235298-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING THIAZOLYL DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-08-19 | — | — | US | disclosed |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY | 2025-08-07 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| CN-118754853-A | Preparation method and application of sulfonamide compound with BRD4 and PARP1 double-target inhibition effect | 扬州大学 | 2024-10-11 | — | — | CN | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | MERCK SHARP & DOHME CORP. | 2007-09-20 | — | — | US | disclosed |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | MERCK SHARP & DOHME CORP. | 2007-09-20 | — | — | US | disclosed |
| EP-1511472-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF ANTHRAX AND INHIBITING LETHAL FACTOR | MERCK & CO INC (US) | 2006-09-27 | — | — | EP | disclosed |
| CN-1655773-A | Compounds useful for treating anthrax and inhibiting lethal factor | MERCK & CO INC (US) | 2005-08-17 | — | — | CN | disclosed |
| US-20050148629-A1 | Compounds useful in the treatment of anthrax and inhibiting lethal factor | MERCK SHARP & DOHME CORP. | 2005-07-07 | — | — | US | disclosed |
| EP-1511472-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF ANTHRAX AND INHIBITING LETHAL FACTOR | Merck & Co., Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003101382-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF ANTHRAX AND INHIBITING LETHAL FACTOR | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | TSHR 1115/4885SMN1; SMN2 2140/4885PTGS2 1092/4885 |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | PLD1, PLD2, NAPEPLD | TSHR 3720/4885SMN1; SMN2 3734/4885PTGS2 1334/4885 |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | APP, PSEN1, BACE1 | TSHR 3462/4885SMN1; SMN2 39/4885PTGS2 4076/4885 |
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | TSHR 772/4885SMN1; SMN2 411/4885PTGS2 1369/4885 |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | TSHR 3998/4885SMN1; SMN2 4551/4885PTGS2 3476/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | TSHR 4751/4885SMN1; SMN2 3096/4885PTGS2 140/4885 |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | ANTXR2, STS, ASNS | TSHR 3345/4885SMN1; SMN2 3064/4885PTGS2 1286/4885 |
| US-20050148629-A1 | Compounds useful in the treatment of anthrax and inhibiting lethal factor | ANTXR2, F12, F11 | TSHR 4389/4885SMN1; SMN2 3964/4885PTGS2 344/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TSHR 4751/4885SMN1; SMN2 3096/4885PTGS2 140/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | TSHR 2225/4885SMN1; SMN2 3627/4885PTGS2 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.